澳大利亚孕产妇呼吸道合胞病毒(RSV)疫苗接种的流行病学影响建模
该研究使用年龄结构房室模型,校准至澳大利亚5岁以下儿童按月汇总的RSV编码住院数据,估计全年孕产妇RSV疫苗接种规划对婴儿及人群的RSV感染和住院影响。在基础假设(疫苗效力、保护期6个月、覆盖率70%)下,<3月龄婴儿RSV住院预测下降60%(从3.0降至1.2/100人),3-5月龄婴儿下降40%(从1.9降至1.1/100人),人群水平RSV感染约减少4%。结论认为,若接种率与其他孕产妇疫苗相当,全年孕产妇RSV疫苗接种规划预计可使6月龄以下婴儿RSV住院数大约减半。
要点
- 基础假设下,<3月龄婴儿RSV住院预测下降60%(从3.0降至1.2/100人)。
- 基础假设下,3-5月龄婴儿RSV住院预测下降40%(从1.9降至1.1/100人)。
- 该规划预测可使人群水平RSV感染约减少4%。
核心结论
- 若接种率与其他孕产妇疫苗在澳大利亚达到的水平相似,全年孕产妇RSV疫苗接种规划预计可使6月龄以下婴儿RSV住院数大约减半。
- 基础情形下预测到小幅 herd effect(群体效应),若疫苗覆盖率或保护持续时间超过基础假设,则可能获得更大获益。
研究设计与样本
- 使用年龄结构房室模型描述RSV传播,并校准至澳大利亚5岁以下儿童按月汇总的RSV编码住院数据。
- 模型纳入母婴互动以更真实地捕捉群体效应,并针对疫苗效力、覆盖率和保护持久性的一系列假设,估计年度年龄别RSV感染和住院的减少量。
主要发现
- 在基础情形疫苗效力、保护期6个月和覆盖率70%的假设下,<3月龄婴儿RSV住院预测下降60%(从3.0降至1.2/100人)。
- 在相同基础假设下,3-5月龄婴儿RSV住院预测下降40%(从1.9降至1.1/100人)。
- 这些获益主要来自对接种疫苗母亲所生婴儿的直接保护。
- 该疫苗规划预测可使人群水平RSV感染约减少4%。
- 覆盖率和保护持续时间假设影响显著:更高覆盖率导致<6月龄婴儿更大降幅,保护持续时间延长则使6-8月龄较大婴儿的感染和住院风险进一步下降。
关键数值与推荐
- 基础情形疫苗效力、保护期6个月、覆盖率70%时,<3月龄婴儿RSV住院从3.0降至1.2/100人(下降60%)。
- 基础情形疫苗效力、保护期6个月、覆盖率70%时,3-5月龄婴儿RSV住院从1.9降至1.1/100人(下降40%)。
- 基础情形下人群水平RSV感染约减少4%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Respiratory syncytial virus (RSV) is a leading cause of respiratory illness among infants. A maternal RSV vaccine that protects young infants has recently been approved for registration in Australia. We estimated the population benefits of a future year-round maternal RSV vaccination program in terms of prevented RSV infections and hospitalisations in Australia. METHODS: We described RSV transmission using an age-structured compartmental model calibrated to Australian aggregated monthly RSV-coded hospitalisations in children aged <5 years. We accounted for mother and infant interactions in the model to capture herd effects more realistically. Using the model, we estimated the annual age-specific RSV infections and hospitalisations prevented for a range of assumptions for vaccine efficacy, coverage, and durability to estimate the future impact of year-round maternal RSV vaccination on infants and the wider population. RESULTS: Assuming base case vaccine efficacy, 6 months duration of protection and 70% coverage, RSV hospitalisations were predicted to fall by 60% (from 3.0 to 1.2 per 100 persons) in infants aged <3 months and 40% (from 1.9 to 1.1 per 100 persons) in 3-5-month-olds. These benefits were primarily due to direct protection to infants of vaccinated mothers. This vaccine program was predicted to reduce the population-level RSV infection by about 4%. Coverage and duration assumptions were influential, with higher coverage leading to larger declines in infants <6 months, and increased duration of protection leading to additional declines in infection and hospitalisation risk in older infants aged 6-8 months. CONCLUSIONS: With vaccine uptake similar to that achieved for other maternal vaccines in Australia, a year-round RSV maternal vaccination program is predicted to approximately halve the number of RSV hospitalisations in infants younger than 6 months. There was a small herd effect predicted in the base case but potential for larger benefits if vaccine coverage or the duration of protection exceeds base case assumptions.
引用
- Nazareno AL, Newall AT, Muscatello DJ, et al. Modelling the epidemiological impact of maternal respiratory syncytial virus (RSV) vaccination in Australia. Vaccine. 2024. PMID: 39423452. doi:10.1016/j.vaccine.2024.126418
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。